KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

The Cochrane database of systematic reviews ·第 2 卷 ·第 2 期 ·2026-02-17

Noordhof A, Asmara OD, de Jong K, Gijtenbeek RG, Huitema YM, van Vollenhoven FH, Venmans BJ, Hendriks L, van Geffen WH

摘要

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of G12C-inhibitors compared to chemotherapy in second line and beyond in adults with advanced/metastatic non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma (KRAS) G12C mutation.

文献信息

期刊

The Cochrane database of systematic reviews

期刊简称

Cochrane Database Syst Rev

ISSN

1469-493X

DOI

10.1016/0197-2456(86)90046-2

发表日期

2026-02-17

语言

英语

国家/地区

England

NLM ID

100909747

外部链接

PubMed 原文 DOI: 10.1016/0197-2456(86)90046-2 查看期刊详情

分析服务

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

联系地址

微信公众号